Newspaper Advertisement for the Standalone & Consolidated Financial Results as on March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aspira Pathlab & Diagnostics has published its audited financial results for Q4 FY25 and the full year ended March 31, 2025 in Business Standard and Parshuram Samachar, as required under SEBI LODR rules. Standalone revenue from operations for the full year rose to ₹2,199.90 lakhs from ₹1,320.49 lakhs in FY24, a growth of about 67%. The company swung to a standalone net profit of ₹207.26 lakhs for FY25, compared with a loss of ₹267.22 lakhs in the previous year. Q4 standalone net profit nearly doubled to ₹72.33 lakhs from ₹37.66 lakhs. Consolidated FY25 net profit stood at ₹202.26 lakhs against a loss of ₹267.22 lakhs in FY24. Basic EPS improved to ₹2.01 (standalone) and ₹1.97 (consolidated) from negative ₹2.60 a year ago.
Strong positive for shareholders — the company posted robust revenue growth and turned a previous year loss into a healthy profit, with EPS swinging positive. This turnaround in earnings is likely to be viewed favorably by the market.